| Date | Title | Description |
| 04.12.2024 | Maze Therapeutics Secures $115 Million to Revolutionize Kidney Disease Treatment | Maze Therapeutics, a beacon of innovation in the biopharmaceutical landscape, has successfully raised $115 million in a Series D financing round. This funding marks a significant milestone for the South San Francisco-based company, which is... |
| 03.12.2024 | Maze Therapeutics: $115 Million (Series D) Raised To Develop Precision Medicine | Maze Therapeutics, a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and metabolic diseases, announced the ... |
| 24.11.2024 | Frazier Healthcare Partners Hits $2.3 Billion Milestone with New Fund | Frazier Healthcare Partners has struck gold again. The Seattle-based private equity firm recently closed its latest flagship fund, the Frazier Healthcare Growth Buyout Fund XI, L.P. (FHGB XI), raising a staggering $2.3 billion. This fund, o... |
| 21.11.2024 | Frazier Healthcare Partners: $2.3 Billion 11th Growth Buyout Fund Closed | Frazier Healthcare Partners, a dedicated healthcare private equity firm, announced the closing of its latest flagship fund, Frazier Healthcare Growth Buyout Fund XI, L.P. (FHGB XI). FHGB XI was significantly oversubscribed, hitting a hard c... |
| 21.11.2024 | Frazier Healthcare Partners Closes $2.3 Billion 11th Growth Buyout Fund | Frazier Healthcare Partners, a Seattle, WA-based dedicated healthcare private equity firm, announced the close of its latest flagship fund, Frazier Healthcare Growth Buyout Fund XI, L.P. (FHGB XI).
Limited partners include public pension fu... |
| 30.10.2024 | GlycoMimetics To Acquire Crescent Biopharma | GlycoMimetics (NASDAQ: GLYC), a Rockville, MD-based late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, acquired Crescent Biopharma, Inc., a biotechnology company advancing a pipeli... |
| 23.10.2024 | Alpha-9 Oncology Raises $175M in Series C Financing | Alpha-9 Oncology Inc., a Boston, MA- and Vancouver, Canada-based clinical stage company developing radiopharmaceuticals to meaningfully improve the treatment of people living with cancer, raised $175m in Series C financing.
The round was le... |
| 31.05.2024 | Private equity's push-pull with health care IT | figcaption>span]:font-sans">
Private equity closed a quarter fewer health care IT (HCIT) deals in Q1 than in the same period last year — despite wanting more exposure to the sector, a PitchBook report finds.
Why it matters: The n... |
| 19.03.2024 | Frazier Healthcare Partners Acquires RevSpring | Frazier Healthcare Partners, a Seattle, WA-based healthcare-focused investment firm, acquired RevSpring, a Nashville, TN-based provider of communication and payment solutions servicing healthcare and financial services companies, from GTCR.... |
| 23.10.2023 | Which VCs are investing in rare diseases? | Firms include Chiesi Ventures, Frazier Healthcare Partners, OrbiMed, and Atlas Venture
In the United States alone 25 million people suffer from rare disease, a number that jumps to 400 million people globally. While 1 in 10 people will suff... |
| 10.08.2022 | The women writing checks: A list of female venture capitalists in the Pacific Northwest | Back in 2018, GeekWire published a list of women investors based in the Pacific Northwest who were writing checks to help startups grow.
A lot has changed in four years. We’ve put together a new compilation below, highlighting more than 60 ... |
| 16.03.2022 | Frazier Healthcare Partners Raises $987 Million Biotech Venture Fund | Frazier Healthcare Partners has raised $987 million for its latest venture fund, adding to the firm’s war chest to invest in biotech companies.
Frazier, which also raised an $830 million public-market fund in October, has now closed on more... |
| 16.03.2022 | 4 South by Southwest predictions about the future of dealmaking | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Happy Wednesday, Term Sheeters!
Paid Content How can authenticity and transparency help build tru... |
| 28.10.2021 | Frazier Healthcare Partners Closes Oversubscribed $830 Million Life Sciences Public Fund | Frazier Healthcare Partners announced today the closing of Frazier Life Sciences Public Fund, L.P., exceeding its target and closing on nearly $830 million in capital commitments in an oversubscribed fundraise.
Led by Managing Partner Alber... |
| 28.10.2021 | Robinhood’s new earnings report raises concerns about the company’s reliance on crypto trading | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Morning, folks. This is Fortune reporter Rey Mashayekhi filling in for Lucinda today.
Well, Robin... |
| 28.10.2021 | Venture Firm Frazier Healthcare Raises $830 Million Public-Market Fund | Frazier Healthcare Partners, a venture-capital firm with a 30-year history of financing biotechnology startups, has raised $830 million for its first public-market fund.
Frazier, founded in 1991, isn’t changing its overall strategy with thi... |
| 28.10.2021 | Robinhood’s new earnings report raises concerns about the company’s reliance on crypto trading | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Si... |
| 30.07.2021 | Takeda and Frazier Healthcare Partners announce collaboration to launch HilleVax, Inc. to develop clinical stage Norovirus Vaccine Candidate | India: Takeda Pharmaceutical Company Limited (TSE:4502/NYSE: TAK) (Takeda) and Frazier Healthcare Partners (Frazier) today announced a collaboration to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company to develop and commerciali... |
| 29.07.2021 | Crinetics Pharmaceuticals Announces $15.0 Million Private Placement with Frazier Healthcare Partners | SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseas... |
| 29.07.2021 | Takeda Pharmaceutical : and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. | Cambridge, Mass. and Menlo Park, Calif., July 29, 2021 - Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (Takeda) and Frazier Healthcare Partners (Frazier) today announced a collaboration to launch HilleVax, Inc. (HilleVax), a bio... |
| 29.07.2021 | Crinetics Pharmaceuticals announces $15.0 million private placement with Frazier Healthcare Partners | - |
| 27.05.2021 | Frazier Healthcare Partners Raises $1.4 Billion | Frazier Healthcare Partners has raised $1.4 billion for its 10th fund to invest in the increasingly popular healthcare sector.
The Seattle firm said it closed Frazier Healthcare Growth Buyout Fund X LP at its hard cap and that it was oversu... |
| 27.05.2021 | PE Firm Frazier Healthcare Partners Closes $1.4B Growth Buyout Fund | What You Should Know:
– Frazier Healthcare Partners, a Seattle-based healthcare private equity firm announced the close of its tenth global buyouts fund and 13th fund across buyouts and life sciences. Investment focus will continue to be mi... |
| 27.05.2021 | Frazier Healthcare Partners raises $1.4B fund, one of the largest in Washington state history | Nader Naini, managing partner at Frazier. (Frazier Photo)
New fund: Seattle-based Frazier Healthcare Partners raised $1.4 billion for its tenth Healthcare Growth Buyout Fund. It’s a big jump from the 30-year-old firm’s most recent $780 mill... |
| 27.05.2021 | Frazier Healthcare Partners Closes $1.4 Billion Growth Buyout Fund | Frazier Healthcare Partners, a Seattle, WA-based healthcare-focused investment firm, closed its 10th dedicated healthcare private equity fund focused on the middle market, at $1.4 billion.
Frazier Healthcare Growth Buyout Fund X, L.P. (FHGB... |
| 18.05.2021 | Hummingbird Bioscience : Raises US$125 Million in Series C Financing | Investment round led by Novo Holdings, joined by a syndicate of international biotech investors
Proceeds will support advancement of Hummingbird's lead assets in clinical trials and building of its next-generation portfolio of precision the... |
| 18.05.2021 | Hummingbird Bioscience Raises US$125 Million in Series C Financing | Investment round led by Novo Holdings, joined by a syndicate of international biotech investors
Proceeds will support advancement of Hummingbird's lead assets in clinical trials and building of its next-generation portfolio of precision the... |
| 17.05.2021 | Hummingbird Bioscience Raises US$125 Million in Series C Financing | |
| 07.01.2021 | Frazier Healthcare Partners Makes Promotions on Life Sciences Team | Venture capital firm Frazier Healthcare Partners announced the promotion of several members on its Life Sciences team.
These are Aditya Kohli to Venture Partner, Anna Chen to Vice President, and Max Nowicki to Senior Associate.
Aditya Kohli... |
| 11.11.2020 | Inipharm raises $35M to combat liver diseases with a genetics approach | Liver diseases, including fatty liver disease, cirrhosis and various rare diseases, have differing causes, from viruses, to drugs, to alcohol, to genetics. However, many of these diseases share effects, including inflammation and fibrosis, ... |
| 11.11.2020 | Inipharm raises $35M to combat liver diseases with a genetics approach
W h i t e p a p e r
Weighing the Costs: | Liver diseases, including fatty liver disease, cirrhosis and various rare diseases, have differing causes, from viruses, to drugs, to alcohol, to genetics. However, many of these diseases share effects, including inflammation and fibrosis, ... |
| 28.07.2020 | Fuse Venture Partners launches to focus on investing in the Pacific Northwest | Founded by Ignition's Kellan Carter and Cameron Borumand, Fuse will invest in B2B software companies
When you think of venture ecosystems, the first that likely come to mind are the Bay Area or New York or Los Angeles. One that doesn't get ... |
| 01.02.2020 | Frazier Healthcare Partners Promotes Four | Venture capital firm Frazier Healthcare Partners promoted Kent Berkley and Ryan Lucero to Principal, and Jennifer Martin and Carol Eckert to Vice President.
The promotions of Berkley and Lucero expand the Principal group on the Growth Buyou... |
| 16.01.2020 | Frazier Healthcare Partners raises $617M life sciences fund | Frazier Healthcare Partners today announced the closure of a $617 million fund, also known as Frazier Life Sciences X. The fresh cash will be used to invest in therapeutics-focused companies developing and commercializing biopharmaceuticals... |
| 16.01.2020 | Frazier Healthcare Partners raises $617M fund to invest in life sciences companies | The firm also made a series of promotions, including Dan Estes to General Partner
Developing new drugs isn't easy, or cheap; in fact, the cost of bringing a new drug to market has been estimated to be over $2 billion. Yet, that's one of the... |
| 16.01.2020 | Frazier Healthcare Partners Completes $617M Life Sciences Fund | Frazier Healthcare Partners, a life sciences focused venture capital firm, closed Frazier Life Sciences X, L.P., at more than $617m.
Frazier Life Sciences X marks the third dedicated Life Sciences fund of the firm, bringing total committed ... |
| 08.11.2019 | Research: October Health IT M&A Activity, Public Company Performance | – Healthcare Growth Partners (HGP) summary of Health IT/digital health merger & acquisition (M&A) activity, and public company performance during the month of October 2019
During the month of October, Health IT continued its evoluti... |
| 29.10.2019 | Frazier Healthcare Partners Anounces Promotions and Additions to Team | Frazier Healthcare Partners, a Seattle, WA-based healthcare investment firm, promoted Ben Magnano to Managing Partner and Phil Zaorski to Principal and added Christina Miller Reszka as a Principal.
Mr. Magnano joined Frazier in 2006 and bec... |
| 30.09.2019 | Enhanced Healthcare Partners Raises $300 Million Of Committed Capital | New York-based private equity firm Enhanced Healthcare Partners announced it closed a fund by raising $300 million of committed capital
Enhanced Healthcare Partners (EHP), a New York-based private equity firm focused on investing in middle-... |
| 03.09.2019 | EW Healthcare Partners Secures $745 Million For New Fund | EW Healthcare Partners recently announced it has raised more than $745 million for the EW Healthcare Partners Fund 2a, L.P.
Growth equity firm EW Healthcare Partners announced it has raised more than $745 million for the EW Healthcare Partn... |
| 23.07.2019 | DW Healthcare Partners Closes Fifth Fund, at $610M | DW Healthcare Partners, a private equity firm focused primarily on making control investments in North American middle market healthcare companies, closed its fifth fund, at $610M.
DW Healthcare Partners V, L.P., oversubscribed, brings the ... |
| 15.05.2019 | Phathom Pharmaceuticals Raises $90M | CAMBRIDGE, Mass. & MENLO PARK, Calif.–(BUSINESS WIRE)– Takeda Pharmaceutical Company Limited and Frazier Healthcare Partners announced a collaboration to launch Phathom Pharmaceuticals, a biopharmaceutical company focused on the develop... |
| 15.05.2019 | Greenspring Associates Joins $90M Financing for Phantom Pharmaceuticals | CAMBRIDGE, Mass. & MENLO PARK, Calif.–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited and Frazier Healthcare Partners announced a collaboration to launch Phathom Pharmaceuticals, a biopharmaceutical company focused on the developm... |
| 27.11.2018 | Frazier Healthcare Partners Adds Mimi Hancock to Life Sciences Team | Venture capital firm Frazier Healthcare Partners has added Mimi Hancock, Ph.D., to its Life Sciences team as a Senior Advisor to assist with attracting top talent for backed companies.
Dr. Hancock has over 20 years of experience in the exec... |
| 15.09.2018 | 40 AND UNDER: The Silicon Valley biotech stars who are backing startups aiming to cure disease, prolong life, and fix the food system | This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Putting millions of dollars into bold new technologies can be a delicate business when lives hang in the balance. But every day some of the... |
| 14.08.2018 | Frazier Healthcare Partners Adds Two to Life Sciences Team | Frazier Healthcare Partners has added two new members to its Life Sciences team.
These include Tracy Saxton, Ph.D. as an Entrepreneur-in-Residence (EIR), and Vanessa Bhark as a Senior Associate.
As an EIR, Dr. Saxton will focus on company c... |
| 10.04.2018 | Frazier Healthcare raises $780 mln growth buyout fund | - |
| 04.01.2018 | Critical Informatics raises $1.1M to expand cybersecurity platform that blends human expertise and software | Critical Informatics pairs software with top-notch security analysts to battle hackers. (Bigstock Photo)
As cybersecurity breaches continue to pile up, a Seattle area startup says it knows what the problem is: too much software, not enough ... |
| 29.11.2017 | Biotech startup scores $20M to develop drug that triggers the immune system to fight cancer | (Shutterstock Photo)
Mavupharma, a biotech startup based in Kirkland, Wash., announced Wednesday that it has raised a $20 million Series A funding round to develop a unique class of drug that enables the body’s immune system to fight cancer... |
| 03.11.2017 | Frazier Healthcare Partners Closes $419M Life Sciences Venture Capital Fund | Frazier Healthcare Partners, a Seattle, WA- and Menlo Park, Calif.-based venture capital firm, closed its latest life sciences fund, at $419M.
Frazier Life Sciences IX, L.P., which marks the second dedicated Life Sciences fund, invests prim... |
| 02.11.2017 | Term Sheet — Thursday, November 2 | SKY HIGH
Good morning, Term Sheet readers.
Paid Content What you need to know about growing cyberattacks From ExtraHop
HOLD THE CHAMPAGNE: HelloFresh, the Germany-based meal kit company, made its market debut, and it wasn’t horrible. In fac... |
| 01.11.2017 | Frazier Healthcare Partners raises $419M for life science venture fund, signaling huge interest in health investment | (Shutterstock Photo)
The U.S. healthcare system faces a myriad of challenges today, including uncertainty over federal regulation and shifting payer systems. You might expect that environment to give pause to many investors.
But if Frazier ... |
| 28.09.2017 | Term Sheet — Thursday, September 28 | DIAL UP THE DRAMA
Good morning, Term Sheet readers!
Paid Content You can't secure what you can't see From ExtraHop
BITCOIN SOUND OFF: The Wolf of Wall Street has spoken. Jordan Belfort, the former stockbroker who pled guilty to fraud, calle... |
| 30.05.2017 | Frazier Healthcare Partners Adds Chris Peetz to Life Sciences Team | Venture capital firm Frazier Healthcare Partners has added Chris Peetz to the Life Sciences team as an Entrepreneur-in-Residence (EIR).
Most recently, Mr. Peetz served as Chief Financial Officer and Head of Corporate Development at Frazier ... |
| 30.05.2017 | Term Sheet — Tuesday, May 30 | The $2.5 BILLION VC FIRM YOU’VE NEVER HEARD OF
Access Technology Ventures is not a household name in Silicon Valley. But in just two years, the New York-based firm has quietly managed to get a piece of numerous hot pre-IPO “unicorn” startup... |
| 15.02.2017 | Term Sheet — Wednesday, February 15 | THE BOLD AND THE DISCIPLINED
Soft-Tress: The big news in Term Sheet’s world this morning is SoftBank Group’s after-hours acquisition of Fortress Investment Group for $3.3 billion. Takes are rolling in hot and fast! (“Neither cheap nor wise!... |
| 14.02.2017 | Frazier Healthcare Partners Adds Two Vice Presidents to Growth Buyout Team | Frazier Healthcare Partners, a provider of growth capital to healthcare companies, expanded its investment team with the promotion of Philip Zaorski and the addition of Ryan Lucero to the Growth Buyout team.
Philip Zaorski, Vice President –... |
| 09.01.2017 | Term Sheet — Monday, January 9 | 10X EXIT, CYBER, FASHION
Good morning, readers. Some quick notes to kick off your week.
It’s a healthy exit for Trello’s investors – sources tell Term Sheet the deal will deliver a multiple of around 10x. The company had raised $10.3 millio... |
| 05.01.2017 | Frazier Healthcare Partners Promotes 3 to Life Sciences Team | Frazier Healthcare Partners, a Seattle, Wash., and Menlo Park, Calif.-based healthcare-focused investment firm, has promoted three investments professionals on the Life Sciences team.
They are Dan Estes, Ph.D. to Partner, Remy Durand, Ph.D.... |
| 17.11.2016 | Rob Kill Joins Frazier Healthcare Partners as Operating Partner on Growth Buyout Team | Industry veteran Rob Kill has joined Frazier Healthcare Partners, a provider of growth capital to healthcare companies, as an Operating Partner on the Growth Buyout team.
Kill will assist the Growth Buyout group with identifying and executi... |
| 10.11.2016 | Term Sheet — Thursday, November 10 | ET CETERA
Hello from Portugal, where Web Summit is underway. Many of the attendees were bleary-eyed yesterday, having stayed up until 4 a.m. watching the U.S. election results on Tuesday. At the conference, the word “Trump” seems to pepper ... |
| 09.11.2016 | Frazier Healthcare Partners Adds Four to Growth Buyout Team | Frazier Healthcare Partners, a Seattle, WA- and Menlo Park, Calif.-based provider of growth capital to healthcare companies, has added Kent Berkley, Jeremy Janson, Neeraj Prathipati, and Shyamal Swami to its Growth Buyout team.
Kent Berkley... |
| 20.09.2016 | Frazier Healthcare Partners Names Amit Jain as an Operating Partner | Frazier Healthcare Partners, a Seattle, Wash., and Menlo Park, Calif.-based provider of growth capital to healthcare companies, named Amit Jain as an Operating Partner on the Growth Buyout team.
Jain will assist the Growth Buyout group with... |
| 15.09.2016 | Hendrik Struik Re-joins Frazier Healthcare Partners as Operating Partner | Frazier Healthcare Partners, a Seattle, Wash., and Menlo Park, Calif.-based provider of growth capital to healthcare companies, announced that Hendrik Struik has re-joined the firm as an Operating Partner on the Growth Buyout team.
Struik w... |
| 07.09.2016 | Frazier Healthcare Partners Adds Brock Hardaway as Operating Partner | Frazier Healthcare Partners, a Seattle, Wash., and Menlo Park, Calif.-based provider of growth capital to healthcare companies, added Brock Hardaway as an Operating Partner on the Growth Buyout team.
He will assist the Growth Buyout team wi... |
| 24.03.2016 | Iterum launches with $40M for novel antibiotic | Most big pharma players have gotten out of the anti-infective space in general, Iterum CEO Corey Fishman said in a phone interview. They’ve chased instead more lucrative opportunities – like drugs for chronic disease, “things people will be... |
| 24.03.2016 | Daily funding roundup - March 24, 2016 | Mesophere received $73.5M investment; Iterum Therapeutics secured $40M; Lagou completed Series C
Malaysia-based Nuren Group, a company that runs a number of women-dedicated content and e-commerce websites, raised $2 million in a Series A ro... |
| 23.03.2016 | Frazier Healthcare launches buyout fund with $525M | Of course, Frazier has a separate fund aimed at earlier stage companies: Just this past October, Frazier Healthcare closed out a $262 million fund to focus exclusively on early stage therapeutics. Two thirds of that fund will be focused on ... |
| 23.03.2016 | Frazier Healthcare Partners Closes Growth Buyout Fund at $525M | Frazier Healthcare Partners, a US-based healthcare-focused investment firm, closed its latest fund at $525m.
Supported by existing and select new limited partners, including endowments, public/private pension funds and financial institution... |
| 23.03.2016 | Seattle biotech investor Robert Nelsen named to Midas List of top performing VCs, propelled by early investment in Juno | Robert Nelsen
Robert Nelsen may not be a household name in venture capital circles — certainly not the way that Reid Hoffman, John Doerr and Fred Wilson are known.
But the Seattle venture capitalist is doing OK, outranking some of the highe... |
| 17.03.2016 | Frazier leads $41m Series A round in startup it co-founded with Japan’s Takeda Pharma | Premium
US-based private equity firm Frazier Healthcare Partners has led a $41-million Series A funding round in Outpost Medicine, a new startup it co-formed with Japanese drug manufacturer Takeda Pharmaceutical Company Limited, according t... |
| 15.03.2016 | Outpost Medicine Completes $41M Financing | Outpost Medicine, a newly formed biopharmaceutical company focused on the development of new treatments of urologic and gynecologic diseases and disorders, completed a $41m financing.
The round was led by Frazier Healthcare Partners with pa... |
| 07.01.2016 | Frazier Healthcare Partners Creates Hawkeye Therapeutics | Seattle, Wash., and Menlo Park, Calif.-based healthcare-focused investment firm Frazier Healthcare Partners announced that Bob Baltera, Howard Dittrich, M.D., and Brian Farmer have joined the Life Sciences team as Entrepreneurs-in-Residence... |
| 05.01.2016 | Daily funding roundup - January 5, 2016 | PAG raised $3.6B; Deciphera Pharmaceuticals raised $90M; Millendo Therapeutics Inc secured $62M
Snapcart, an Indonesia-based cashback app, has raised $1.675 million in "pre-series A funding". Investors in this round include SPH Me... |
| 29.10.2015 | Frazier Healthcare Partners Closes Fund VIII, at $262M | Frazier Healthcare Partners, a Seattle, Wash.- and Menlo Park, CA-based healthcare-focused investment firm, closed its fund VIII, at $262m.
As the firm’s first sector-specific fund, Frazier Life Sciences VIII will invest exclusively in comp... |
| 29.10.2015 | Touting A New Strategy, Frazier Healthcare Partners Closes A $262 Million New Fund | Frazier Healthcare Partners, a 24-year-old venture firm that invests only in healthcare and has offices in both Seattle and Menlo Park, Ca., has just closed its eighth fund with $262 million from mostly earlier backers.
While a coup, the po... |
| 20.10.2014 | Daily funding roundup - October 20, 2015 | Yidao Yongche bagged $700M; Gritstone Oncology raised $102M; Zignal Labs landed $15M
Zignal Labs, a realtime cross media analytics company, today announced the completion of a $15 million round of funding. The round was led by existing inve... |
| 22.07.2014 | MoneyTree Reports $121M in MI Venture Deals Last Quarter | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Venture Capital investors had a very active second quarter of 2014, according to the latest MoneyTree report. VCs invested almost $13 billion in 1,114 U.S. startups during the... |
| 12.06.2014 | Wearable Maker Chrono Raises $32 Million So Smokers Can Kick The Habit | Smoking-related illnesses kill more than 400,000 Americans each year, including a relative of Guy DiPierro, the founder of Chrono Therapeutics, a startup that raised $32 million to develop a wearable drug delivery and treatment technology t... |
| 22.04.2014 | ProNAi Therapeutics Closes on $59.5M to Advance Cancer Drug | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
ProNAi Therapeutics, a Plymouth, MI-based developer of novel nucleic acid treatments targeting cancer and other genetic diseases, said this week that it has closed a Series D ... |
| 21.04.2014 | ProNAi raises $60 million to advance treatment to combat lymphoma | Among the applications for its PNT2258 treatment are diffuse large B-cell lymphoma, Richter’s transformation, and follicular lymphoma. The funds will also support drug manufacturing, advance development of preclinical drug candidates and th... |
| 04.12.2013 | Healthcare VC on the rebound? 5AM Ventures quickly raises its biggest fund yet | And there’s a reason for that. This year, 5AM portfolio companies Incline Therapeutics and Pearl Therapeutics were snatched up by The Medicines Company and AstraZeneca, respectively. Relypsa and KaloBios also both went public.
Amid a boom o... |
| 01.10.2013 | Frazier Healthcare Closes Seventh Fund at $377M | Menlo Park, Calif. and Seattle, Washington-based Frazier Healthcare closed its seventh fund at $377m.
Frazier Healthcare VII (FH VII) was funded by corporate and public pension plans, foundations, endowments, and fund of funds.
Founded in 1... |
| 03.07.2013 | Iguana Healthcare Partners raises $54M investment fund | Wall Street Beat | New York-based lifesciences investment group Iguana Healthcare Partners filed an amended notice, reporting that the company has raised more than $53.5 million in pooled investment fund interests.
The funding, raised among 20 unnamed investo... |
| 13.07.2012 | Biopharmaceutical VC firm Frazier Healthcare raising new $400 million fund | The firm’s investment strategy focuses on companies with development-stage biopharmaceutical therapeutics and occasionally medical devices.
Unlike other firms focusing on mass markets like diabetes, obesity, cardiovascular disease and neuro... |
| 09.07.2012 | Early stage fundraising by venture firms doubles, health IT companies likely to benefit | The bulk of venture capital fundraising in the second quarter was done by the fewest number of funds in nearly three years, according to statistics from the National Venture Capital Association and Thompson Reuters.
About 38 U.S. venture ca... |
| 03.07.2012 | Frazier Healthcare files to raise a $400 million venture fund | Frazier Healthcare, a 21-year-old venture capital firm with offices in Seattle and Silicon Valley, has filed documents with the Securities and Exchange Commission to raise up to $400 million for its seventh venture fund.
The firm was founde... |
| 20.02.2012 | Are new life science investors eyeing Research Triangle Park? | Plus, the recent CED Life Science Conference had a series of new investor faces in the audience, as well as some prodigal sons. A few I spoke with said they were there because they thought there were deals to be done that the typical Park i... |
| 16.11.2011 | Allena Pharmaceuticals Raises $15M in Series A Venture Capital Financing | Allena Pharmaceuticals, Inc., a Newton, Mass.-based company developing and commercializing innovative non-systemic oral protein therapeutics, has secured $15m in Series A venture capital financing.
Backers include Bessemer Venture Partners,... |
| 09.11.2011 | Rempex Pharmaceuticals Completes Initial Closing of $67.5M Series B Financing | Rempex Pharmaceuticals, Inc., a San Diego, CA-based biopharmaceutical company that focuses on developing internally discovered new treatments for resistant gram-negative infections has completed the initial closing of a Series B financing.
... |
| 28.06.2011 | Tech moves: Conrad Saam joins Urbanspoon; Monica Guzman leaves Intersect; and more | Saam
We’ve been tracking some key hires and people on the move in the Seattle tech industry in recent days. Here are a few…
Conrad Saam has left Avvo to take on the role of vice president of marketing at Urbanspoon, the Seattle online resta... |
| 29.03.2011 | Frazier Healthcare buys Onsite Services | Seattle venture capital firm Frazier Healthcare has purchased Onsite Services, an instrument and management repair business previously owned by publicly-traded by CareFusion. The terms of the deal were not disclosed.
OnSite Services employs... |
| 02.11.2010 | Provident Healthcare Ventures Launches $25M Fund | Provident Healthcare Ventures, LLC, has launched its $25m maiden fund that will focus on investing in early-stage healthcare services companies.
The Principals Fund I includes both an incubator for early-stage start-up funding, as well as m... |
| 22.02.2010 | OrbiMed Advisors raises $550M for health venture fund | Last year, OrbiMed led a $25 million Series B round for Oakwood-based ViewRay, which is developing a device that uses MRIs to guide gamma rays to target cancerous tumors. OrbiMed lists Cleveland-based stem cell developer Athersys as one of ... |
| 18.02.2009 | Public biotech firms Cadence, Affymax draw $128M from bargain-hunting VCs | Much has been written about how the IPO market froze out biotech companies in 2008, but it looks like times are also tough for those who went public before the economy soured. Cadence Pharmaceuticals has seen a dip in stock price from $9 to... |
| 07.01.2009 | Intradigm closes $21.4M for cancer therapeutics | Biotech firm Intradigm has tacked an additional $2.9 million onto its second round of funding, bringing its total to $21.4 million. The new money will be used to advance its RNA interference-based line of therapeutics used to treat cancer.
... |
| 20.11.2008 | Arete nabs $16.7M more to treat metabolic disorders | Biotech company Arete Therapeutics brought in $16.7 million in the final tranche of a first round of funding that now totals $51 million. The Hayward, Calif.-based company will use the money to push its lead treatment for metabolic syndrome... |
| 14.10.2008 | Migraine sufferers look elsewhere as Cierra buckles | The headache is over for medical device maker Cierra. Actually it’s all over. The Redwood City, Calif.-based company is out of business after failing to draft enough participants into a clinical trial of a catheter-based technology purporte... |
| 03.10.2008 | Intradigm lands $18.5M to advance oncology treatment | Intradigm, a biotech company that develops RNA interference treatments for cancer, announced today that it took $18.5 million in a second round of financing that included new investors Lilly Ventures, Roche Venture Fund, MP Healthcare Ventu... |
| 30.07.2008 | EBR Systems gets $35 million for new style pacemaker | EBR Systems, which develops cardiac pacing devices, has raised a $35 million third round of financing. This money will help it take its product to clinical trials, according to VentureWire.
Delphi Ventures led this round, with existing inve... |
